Last reviewed · How we verify
Brimonidine 0.33% gel (Br)
Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces redness in the skin.
Brimonidine is an alpha-2 adrenergic agonist that constricts blood vessels and reduces redness in the skin. Used for Persistent facial erythema associated with rosacea.
At a glance
| Generic name | Brimonidine 0.33% gel (Br) |
|---|---|
| Sponsor | Galderma R&D |
| Drug class | Alpha-2 adrenergic agonist |
| Target | Alpha-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Brimonidine selectively binds to alpha-2 adrenergic receptors on vascular smooth muscle cells, causing vasoconstriction that reduces blood flow to the skin surface. This topical gel formulation is applied directly to facial erythema (redness), where it decreases visible flushing and persistent redness by narrowing capillaries in the affected areas. The effect is temporary and localized to the application site.
Approved indications
- Persistent facial erythema associated with rosacea
Common side effects
- Erythema (localized redness)
- Skin irritation or burning
- Pruritus (itching)
- Pallor (whitening of skin)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine 0.33% gel (Br) CI brief — competitive landscape report
- Brimonidine 0.33% gel (Br) updates RSS · CI watch RSS
- Galderma R&D portfolio CI